604 Shares in McKesson Corporation $MCK Purchased by Parkwoods Wealth Partners LLC

Parkwoods Wealth Partners LLC purchased a new stake in shares of McKesson Corporation (NYSE:MCK) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 604 shares of the company’s stock, valued at approximately $495,000.

Several other hedge funds have also bought and sold shares of the business. Obsidian Personal Planning Solutions LLC increased its stake in shares of McKesson by 2.9% during the third quarter. Obsidian Personal Planning Solutions LLC now owns 426 shares of the company’s stock valued at $346,000 after purchasing an additional 12 shares in the last quarter. IAM Advisory LLC boosted its position in shares of McKesson by 0.3% in the 3rd quarter. IAM Advisory LLC now owns 3,908 shares of the company’s stock worth $3,019,000 after purchasing an additional 13 shares in the last quarter. PDS Planning Inc boosted its position in shares of McKesson by 1.1% in the 3rd quarter. PDS Planning Inc now owns 1,209 shares of the company’s stock worth $934,000 after purchasing an additional 13 shares in the last quarter. Berkshire Asset Management LLC PA grew its stake in shares of McKesson by 4.6% in the 3rd quarter. Berkshire Asset Management LLC PA now owns 294 shares of the company’s stock worth $227,000 after buying an additional 13 shares during the last quarter. Finally, Norden Group LLC grew its stake in shares of McKesson by 4.3% in the 4th quarter. Norden Group LLC now owns 317 shares of the company’s stock worth $260,000 after buying an additional 13 shares during the last quarter. Institutional investors own 85.07% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on MCK. Barclays lifted their price objective on McKesson from $960.00 to $1,050.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Morgan Stanley restated an “overweight” rating and set a $966.00 price target on shares of McKesson in a report on Thursday, January 29th. Mizuho lifted their price target on McKesson from $880.00 to $885.00 and gave the stock a “neutral” rating in a research report on Thursday, February 5th. Wells Fargo & Company upped their price target on shares of McKesson from $914.00 to $925.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 5th. Finally, JPMorgan Chase & Co. increased their price objective on shares of McKesson from $983.00 to $1,107.00 and gave the company an “overweight” rating in a research report on Tuesday, February 10th. Thirteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $960.93.

McKesson Trading Up 0.0%

Shares of MCK opened at $860.37 on Tuesday. The company has a market cap of $105.39 billion, a price-to-earnings ratio of 24.74, a P/E/G ratio of 1.38 and a beta of 0.38. The business’s fifty day simple moving average is $908.02 and its two-hundred day simple moving average is $841.69. McKesson Corporation has a 12 month low of $637.00 and a 12 month high of $999.00.

McKesson (NYSE:MCK) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, topping the consensus estimate of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The firm had revenue of $106.16 billion during the quarter, compared to analysts’ expectations of $105.98 billion. During the same quarter in the previous year, the business earned $8.03 earnings per share. The company’s revenue was up 11.4% on a year-over-year basis. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, research analysts forecast that McKesson Corporation will post 32.77 EPS for the current year.

McKesson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be paid a dividend of $0.82 per share. The ex-dividend date is Monday, March 2nd. This represents a $3.28 annualized dividend and a yield of 0.4%. McKesson’s dividend payout ratio is currently 9.43%.

Insider Buying and Selling at McKesson

In other news, EVP Thomas L. Rodgers sold 276 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $816.18, for a total transaction of $225,265.68. Following the completion of the transaction, the executive vice president directly owned 2,268 shares of the company’s stock, valued at $1,851,096.24. The trade was a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Maria Martinez sold 349 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $939.87, for a total transaction of $328,014.63. Following the transaction, the director owned 301 shares in the company, valued at approximately $282,900.87. This trade represents a 53.69% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 3,868 shares of company stock worth $3,743,820. 0.08% of the stock is owned by company insiders.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.